- Home
- TBLA vs LTGO Comparison
TBLA vs LTGO Comparison
Compare TBLA & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TBLA | LTGO |
|---|---|---|
| Founded | 2007 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.2B |
| IPO Year | 2021 | 2026 |
Fundamental Metrics
Financial Performance| Metric | TBLA | LTGO |
|---|---|---|
| Price | $3.86 | $23.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 2.6M | 283.6K |
| Earning Date | 05-06-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1400.00 | N/A |
| EPS | ★ 220.00 | N/A |
| Revenue | ★ $1,912,040,000.00 | N/A |
| Revenue This Year | $7.63 | N/A |
| Revenue Next Year | $5.25 | N/A |
| P/E Ratio | $0.02 | ★ N/A |
| Revenue Growth | ★ 8.26 | N/A |
| 52 Week Low | $2.84 | $17.22 |
| 52 Week High | $5.71 | $25.93 |
Technical Indicators
Market Signals| Indicator | TBLA | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 41.50 | 61.51 |
| Support Level | $3.59 | $21.26 |
| Resistance Level | $3.94 | $25.47 |
| Average True Range (ATR) | 0.15 | 1.87 |
| MACD | 0.04 | -0.04 |
| Stochastic Oscillator | 57.50 | 44.44 |
Price Performance
Historical ComparisonAbout TBLA Taboola.com Ltd.
Taboola is a performance-based native advertising network designed to improve click-through rates and increase monetizable events for advertisers while generating yield for publisher websites. Taboola competes with Google, Amazon, and other advertising networks that display stories and products on websites. The company was founded in 2007 in Israel. It acquired Connexity, a retail advertising network, in 2021, and entered a partnership with Yahoo in 2022, in which it acquired exclusive native advertising rights over Yahoo digital properties in exchange for a 25% equity stake in the company.
About LTGO Latigo Biotherapeutics Inc. Common Stock
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.